Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInsel Gruppe AG, University Hospital Bern
About this trial
In this study the investigators retrospectively and prospectively collect information from enrolled subjects undergoing CCTA and evaluate the association of cardiac and non-cardiac imaging with laboratory markers and clinical data including outcome.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult individual >18 years
Undergoing clinically indicated CCTA
Signed informed consent or waiver
Disqualifiers
None
Trial population
The registry foreseen a prospective cohort composed by patients undergoing clinically indicated CCTA and by a retrospective population of patients that have undergone CCTA 1st June 2017 to 31st December 2020. The principal investigator confirms that no patient's personal health data will be collected if a written or documented oral refusal exist.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
4,200 Participants
are grouped into 1 trial groupGroup A: Patients undergoing clinically indicated CCTA
Trial outcomes
Primary outcomes
1
All-cause death.
The primary endpoint is the time to first occurrence of death from all-causes.
Time frame
10 yearsSecondary outcomes
1
Major adverse cardiovascular events (MACE)
The secondary composite endpoint is major adverse cardiac events (MACE), which is defined by the occurrence of any of the following events: 1. All-cause death 2. Myocardial infarction 3. Unstable angina-related hospitalization 4. Late coronary revascularization (≥90 days)
Time frame
10 years2
Other outcome
Occurrence of any of the following events: 1. Cerebrovascular accident 2. Valvular intervention 3. Congestive heart failure-related hospitalization 4. Cardiac death
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Insel Gruppe AG, University Hospital Bern
Lead sponsor
University Hospital, Zürich
Collaborator
Source ClinicalTrials.gov